Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?
Publication
, Journal Article
Urban, TJ; Goldstein, DB; Watkins, PB
Published in: Pharmacogenomics
May 2012
Drug-induced liver injury (DILI) is a rare but severe adverse drug reaction that represents a major problem in pharmacotherapy, both clinically and economically. A considerable effort has been made over the past several decades to identify genetic factors that predispose to risk for DILI, and the pace of discovery has vastly increased over just the past several years. Here, we describe the major findings in DILI pharmacogenetics with an emphasis on the recent results of unbiased genome-wide association studies, and suggest some directions for future research in this area.
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Pharmacogenomics
DOI
EISSN
1744-8042
Publication Date
May 2012
Volume
13
Issue
7
Start / End Page
735 / 738
Location
England
Related Subject Headings
- STAT4 Transcription Factor
- Polymorphism, Single Nucleotide
- Pharmacology & Pharmacy
- Isoniazid
- Humans
- Genome-Wide Association Study
- Genetic Predisposition to Disease
- Floxacillin
- Chemical and Drug Induced Liver Injury
- Arylamine N-Acetyltransferase
Citation
APA
Chicago
ICMJE
MLA
NLM
Urban, T. J., Goldstein, D. B., & Watkins, P. B. (2012). Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? Pharmacogenomics, 13(7), 735–738. https://doi.org/10.2217/pgs.12.45
Urban, Thomas J., David B. Goldstein, and Paul B. Watkins. “Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?” Pharmacogenomics 13, no. 7 (May 2012): 735–38. https://doi.org/10.2217/pgs.12.45.
Urban TJ, Goldstein DB, Watkins PB. Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? Pharmacogenomics. 2012 May;13(7):735–8.
Urban, Thomas J., et al. “Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?” Pharmacogenomics, vol. 13, no. 7, May 2012, pp. 735–38. Pubmed, doi:10.2217/pgs.12.45.
Urban TJ, Goldstein DB, Watkins PB. Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? Pharmacogenomics. 2012 May;13(7):735–738.
Published In
Pharmacogenomics
DOI
EISSN
1744-8042
Publication Date
May 2012
Volume
13
Issue
7
Start / End Page
735 / 738
Location
England
Related Subject Headings
- STAT4 Transcription Factor
- Polymorphism, Single Nucleotide
- Pharmacology & Pharmacy
- Isoniazid
- Humans
- Genome-Wide Association Study
- Genetic Predisposition to Disease
- Floxacillin
- Chemical and Drug Induced Liver Injury
- Arylamine N-Acetyltransferase